Bridge to Life's HOPE System Shows Promise in Pediatric Liver Transplants
Event summary
- Bridge to Life's VitaSmart Hypothermic Oxygenated Machine Perfusion (HOPE) System demonstrated safety and effectiveness in partial graft pediatric liver transplantation.
- Study with 17 pediatric liver recipients showed 100% death-censored graft survival and a 27% reduction in cold ischemic times.
- Two additional studies presented at SPLIT 2026 further supported the use of HOPE in pediatric liver transplantation.
- Bridge to Life aims to make HOPE a standard of care for partial graft utilization in pediatric liver transplantation.
The big picture
Bridge to Life's HOPE System is positioning itself as a potential standard of care in pediatric liver transplantation, addressing critical issues around organ viability and graft function. The technology could significantly improve outcomes for partial graft transplants, a growing need in pediatric healthcare. The company's focus on increasing the supply of available livers aligns with broader industry trends towards enhancing organ preservation and transplantation success rates.
What we're watching
- Adoption Pace
- How quickly transplant centers will adopt HOPE for pediatric liver transplants, especially for partial grafts.
- Regulatory Approval
- Whether Bridge to Life can secure regulatory approvals to expand the use of HOPE in other transplant scenarios.
- Market Expansion
- The pace at which Bridge to Life can expand the use of HOPE into other organ types or adult transplant procedures.
Related topics